Myfortic (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myfortic, is an Antimetabolite presented as a delayed‑release tablet for oral use. It is used to prevent organ rejection in patients who have undergone renal, heart or liver transplantation. GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Myfortic is an immunosuppressant that acts on the lymphocyte proliferation pathway to reduce transplant rejection. - Renal transplantation: helps prevent organ rejection in kidney transplant recipients. - Heart transplantation: reduces the risk of heart graft rejection. - Liver transplantation: supports long‑term graft survival by inhibiting immune‑mediated damage.

Adverse reactions may occur with Myfortic and should be monitored.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools that may affect hydration. - Headache: intermittent pain often relieved with rest. - Tremor: fine shaking of hands or limbs.

Serious or Rare Side Effects: - Infections: increased susceptibility to bacterial, viral or fungal infections. - Leukopenia: significant reduction in white blood cell count. - Hepatotoxicity: elevated liver enzymes indicating possible liver injury.

Patients receiving Myfortic should be monitored for safety and efficacy. - Monitor blood counts: regular CBC to detect leukopenia or anemia. - Monitor liver function: periodic LFTs to identify hepatotoxicity. - Avoid live vaccines: risk of uncontrolled infection due to immunosuppression. - Use caution in renal impairment: dose adjustment may be required. - Pregnancy and breastfeeding: safety not established; discuss risks with a healthcare professional. - Store at ambient temperature: keep in the original pack, protect from moisture.

Myfortic can interact with several medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: may reduce absorption of Myfortic. - Rifampin: induces metabolism, decreasing drug levels. - Cyclosporine: combined use can increase risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression. - NSAIDs: may enhance renal adverse effects. - Live vaccines: heightened infection risk when used together.